Medical News

Raltegravir Demonstrates Long-term Safety and Efficacy in Japanese Settings

In Japan, antiretroviral agents are approved on the basis of non-clinical and clinical data reported from overseas. However, evidence suggesting...

23 Jan, 2019

 
Email this page
Clinical and Treatment Outcomes in HIV-infected and HIV-uninfected Patients with Motor Neuron Disease

A recent retrospective analysis comparing the clinical and treatment outcomes in   HIV-infected patients with motor neuron syndrome (MNS) and HIV-...

11 Jan, 2019

 
Email this page
EFV as Safe as other ART Drugs During Pregnancy, Suggests a Recent Study

A recent analysis investigating the association between efavirenz (EFV) use during conception or first trimester (T1) of pregnancy and the...

09 Jan, 2019

 
Email this page
Elbasvir/Grazoprevir Demonstrate No Clinically Relevant Drug Interaction with Raltegravir and Dolutegravir

Elbasvir/grazoprevir is a once-daily fixed-dose combination therapy for the treatment of chronic HCV infection, including HCV/HIV co-infection. ...

08 Jan, 2019

 
Email this page

Key Trials

Safety and Efficacy of E/C/F/TAF vs E/C/F/TDF in Treatment Naïve HIV Patients

This trial compares the safety and efficacy of TAF vs TDF co-formulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of...

REALITY: Enhanced Antimicrobial Prophylaxis + ART Improves Survival in Advanced HIV Patients

This study compared the enhanced and standard antimicrobial prophylaxis treatment in patients with advanced HIV disease.

Pre-exposure Chemoprophylaxis with Oral FTC–TDF Prevents HIV Acquisition in Men Who have Sex with Men

Pre-exposure Prophylaxis Initiative (iPrEx) trial was a randomized, double-blind, placebo controlled trial aimed to evaluate the safety and efficacy...

Partners PrEP Study: Oral TDF or TDF–FTC Significantly Reduces the Risk of HIV-1 Acquisition among Heterosexual Men and Women in Serodiscordant Relationships

The Partners PrEP Study is a double-blind, placebo-controlled, phase III clinical trial aimed to assess the safety and efficacy of oral PrEP for the...

Our Publications

Nutshell Series 2: Tuberculosis Infection and Disease

Tuberculosis (TB) is the most common presenting illness and is one of the leading causes of death in people with HIV, particularly in low-income...

Patient Education

Live Healthier, Live Longer

This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment...

Living with Hope

This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects...

Slide Library

HIV - HCV Coinfection

This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...

 
Email this page
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use

PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...

 
Email this page
HIV- Post-exposure Prophylaxis (PEP)

Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...

 
Email this page
Isoniazid Preventive Therapy in HIV Infection

HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....

 
Email this page

Poll

Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
67% (2 votes)
Efavirenz 400
0% (0 votes)
Dolutegravir
33% (1 vote)
Total votes: 3